Literature Analysis of the Serious Immune-related Adverse Reactions of Lamotrigine

Abstract

Abstract: Objective To analyze the serious immune-related adverse reactions caused by lamotrigine and provide reference for the clinical rational drug use. Methods The related adverse reactions reported in domestic and foreign literatures were systematically retrieved, such as cases, reviews, studies, etc., and the manifestations, characteristics and mechanism of lamotrigine-induced severe immune-related adverse reactions were reviewed. Results Lamotrigine can cause serious immune-related adverse reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, immune hemolytic anemia, systemic lupus erythematosus, pseudolymphoma, limbic encephalitis, and hemophagocytic lymphohistiocytosis, occurring from a few days to several years after administration. Different immune-related adverse reactions have different mechanisms of occurrence, and some adverse reactions are rare but very severe or even fatal. Conclusion Medical staff should pay attention to the risk of serious immune-related adverse reactions of lamotrigine and timely diagnosis and treatment. It is recommended that manufacturers strengthen research and increase warnings about adverse reactions in the instructions to avoid serious consequences.

Key words: immune-related adverse reactions, lamotrigine, drug reaction with eosinophilia and systemic symptoms, systemic lupus erythematosus, hemophagocytic lymphohistiocytosis

CLC Number:

R994.11

QIU Bo, ZHOU Juan, TIAN Yuejie. Literature Analysis of the Serious Immune-related Adverse Reactions of Lamotrigine[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 603-607.

References

[1] FDA. FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine(Lamictal)[EB/OL].(2018-04-25)[2018-07-31].https://www.fda.gov/Drugs/DrugSafety/ucm605470.htm.
[2] Perronnin M, Pichetti S, Sermet C.Lamotrigine-induced rash-worth a rechallenge[J]. Acta Neurologica Scandinavica, 2005, 111(3):191-194.
[3] FDA. LAMICTAL label[EB/OL]. (2015-03-24)[2018-08-07]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020241s045s051lbl.pdf.
[4] 何心, 张永, 徐进, 等. 77例拉莫三嗪不良反应的文献分析[J]. 中国药物警戒,2016,13(5):303-305.
[5] Han S H, Hur M S, Youn H J, et al.Drug Reaction with Eosinophilia and Systemic Symptom Syndrome Induced by Lamotrigine[J]. Ann Dermatol, 2017 ,29(2):206-209.
[6] Wang X Q, Lv B, Wang H F, et al.Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients[J]. Clinical Neurology & Neurosurgery, 2015, 138:1-7.
[7] Mehrholz D, Urban A E, Herstowska M, et al.A retrospective study of DRESS - drug reaction with eosinophilia and systemic symptoms[J]. Psychiatria Polska, 2017, 51(6):1079-1093.
[8] 方圣博, 张晓荧, 张欣, 等. 拉莫三嗪致儿童高敏综合征1例[J]. 药物流行病学杂志, 2018,27(3):213-214.
[9] Barbaryan A, Iyinagoro C, Nwankwo N, et al.Ibuprofen-induced hemolytic anemia[J]. Case Rep Hematol, 2013, 2013(2013):142865.
[10] 艾奇, 王欣, 乔丽津. 拉莫三嗪诱发溶血性贫血2例[J]. 中国医院药学杂志, 2016, 36(8):699-700.
[11] Sarziputtini P, Panni B, Cazzola M, et al.Lamotrigine-induced lupus[J]. Lupus, 2000, 9(7):555.
[12] Ravindran V.Lamotrigine-induced lupus: a case report[J]. International Journal of Rheumatic Diseases, 2011, 14(3):e47-e48.
[13] 田防震, 田华. 拉莫三嗪诱发SLE 1例[J]. 中国麻风皮肤病杂志, 2006, 22(2):176-177.
[14] Chang R S, Cole A J.Lamotrigine-Induced Lupus-Like Syndrome: A Case Report and Literature Review[J]. American Journal of Therapeutics, 2012, 21(3):e85.
[15] Cabanillas M, Suárez-Amor O, Ramírez-Santos A, et al.Lamotrigine induced subacute cutaneous lupus erythematous[J]. Dermatology Online Journal, 2012, 18(8):12.
[16] Pathak P, Mclachlan R S.Drug-induced pseudolymphoma secondary to lamotrigine[J]. Neurology, 1998, 50(5):1509.
[17] Mulroy E, Walker E.Lamotrigine-related pseudolymphoma presenting as cervical lymphadenopathy[J]. Epilepsy & Behavior Case Reports, 2017, 7(C):40-41.
[18] Reed Do K L, Quinn Do K, Gust A J. Cutaneous Pseudolymphoma Due to Lamotrigine: First Reported Case[J]. Hospital Pharmacy, 2015, 49(2):164-169.
[19] Stephan F, Haber R, Kechichian E, et al.Lamotrigine-induced Hypersensitivity Syndrome with Histologic Features of CD30+ Lymphoma[J]. Indian J Dermatol, 2016, 61(2):235.
[20] Ozisik L, Tanriover M D, Saka E.Autoimmune Limbic Encephalitis and Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Lamotrigine-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome[J]. Internal Medicine, 2016, 55(10):1393-1396.
[21] Jan-Inge Henter, AnnaCarin Horne, Maurizio Aricó, et al. HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatric Blood & Cancer, 2007, 48(2):124-131.
[22] Ignaszewski M, Ignaszewski M J, Kohlitz P.Lamotrigine-Associated Hemophagocytic Lymphohistiocytosis[J]. American Journal of Therapeutics, 2017, 24(4):e493.
[23] Koh M J, Tay Y K.An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children[J]. Current Opinion in Pediatrics, 2009, 21(4):505.
[24] Kardaun S H, Sidoroff A, Valeyrie-Allanore L, et al.Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?[J]. British Journal of Dermatology, 2007, 156(3):609-611.
[25] Shiohara T, Iijima M, Ikezawa Z, et al.The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations[J]. British Journal of Dermatology, 2010, 156(5):1083-1084.
[26] 沈璐, 李馨龄, 刘巍, 等. 儿童与成人使用拉莫三嗪发生不良事件之比较-英国运用处方事件监测开展儿童上市后药物警戒之介绍[J]. 中国药物警戒, 2012, 9(10):607-614.
[27] 高阳, 于爱平, 蒋玉凤, 等. HLA-B*1502等位基因与中国南方汉族癫痫患者拉莫三嗪皮肤不良反应关联性的Meta分析[J]. 中国医院药学杂志, 2016, 36(2):110-114.
[28] 张婷, 肖农. 拉莫三嗪所致严重皮肤性药物不良反应的研究进展[J]. 中华神经科杂志, 2013, 46(12):850-852.
[29] Magro C M, Crowson A N, Kovatich A J, et al.Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells[J]. Human Pathology, 2003, 34(2):119-129.
[30] TGA.Lamotrigine and serious skin reactions [EB/OL].(2010-11-30) [2018-08-01].https://www.tga.gov.au/publication-issue/medicines-safety-update-no6-2010.